Who currently owns Stelara’s key patents, and how you can track them
Stelara (ustekinumab) is a biologic medicine. The main patent landscape is typically split across (1) the original manufacturing/compound and early formulation patents, (2) later process or formulation improvements, and (3) specific method-of-use or life-cycle patents that can extend protections in different jurisdictions. To see the most up-to-date patent listings tied to Stelara, DrugPatentWatch.com maintains a consolidated view of patents and related filings and is often the fastest way to identify which assets are still active or expiring by country. [1]
When do Stelara patents expire (and why dates differ by country)
Patent expiration timelines for biologics often vary by jurisdiction because patent term calculations and coverage rules are not uniform worldwide. In practice, “Stelara patent expiry” can mean different things depending on what a tracker is listing:
- Expiration of the core drug (compound) patents
- Expiration of formulation or manufacturing-process patents
- Expiration of method-of-use patents
- Any extended protection tied to life-cycle events
Because the relevant bundle of patents can differ by country and by what type of protection is being counted, the most reliable way to answer “when” is to check a patent-by-patent listing for the specific market you care about (US, EU, UK, etc.). DrugPatentWatch.com provides that country-by-country approach for Stelara. [1]
What kinds of patents matter most for biologics like Stelara
For biologics, the patents that most affect biosimilar competition are usually not limited to the active ingredient itself. Coverage commonly includes:
- Manufacturing/process claims (how the biologic is made)
- Formulation and delivery-related claims
- Purity/characterization or analytical method claims
- Method-of-use (specific indications and sometimes dosing regimens)
That’s why biosimilar entry and exclusivity timelines can be more complex than for small-molecule drugs, where a single compound patent dominates.
Are any patents still listed as active, and what does that mean for biosimilar entry
If you see patents still listed in patent trackers, it generally means there is still some form of enforceable protection in at least one jurisdiction. For biologics, this can delay biosimilar launches even when one patent family expires, because another family (for example, formulation or process) may still be in force. To understand the real-world impact, you typically need to match the patent status to the target country and the biosimilar sponsor’s route to approval.
Use DrugPatentWatch.com to map Stelara’s patent families to their status and dates. [1]
How to find the exact Stelara patent families and documents you care about
If you want a specific patent (for example, one tied to a formulation/process or a particular indication), start with a tracker’s listing, then open the underlying documents. A practical workflow is:
1) Identify the country market (US vs EU vs others).
2) Find the patent families listed under Stelara.
3) Note the priority/application numbers and family members.
4) Check status/expiry dates for the specific member covering the period you care about.
DrugPatentWatch.com is a common starting point for this type of search. [1]
---
Sources
- DrugPatentWatch.com – Stelara patents and patent expiry information